# 製藥巨頭Wockhardt股價週一飆升超過10%。

*biotech · news · 2026-06-01 · Moneycontrol*

## Key points

- Wockhardt獲得美國FDA批准其針對耐藥革蘭氏陰性菌的新型抗生素Zaynich。
- Zaynich用於治療複雜性尿路感染，包括腎盂腎炎，並對抗抗微生物藥物抗藥性。
- 該藥物的全球可及市場估計為90億美元，其中美國和歐洲佔70億美元。
- Wockhardt是少數獲得美國和印度監管機構批准專有抗生素的印度公司之一。
- 大型製藥公司已退出抗生素研究，留下市場空缺，Wockhardt正瞄準此機會。

Shares of pharma major Wockhardt surged more than 10% on Monday after the company secured US Food and Drug Administration (FDA) approval for its novel antibiotic Zaynich, a major milestone in its decades-long research effort. The stock had surged as much as 16.21% at the opening trade following the FDA approval announcement before paring some gains. It was still up 12.2% at Rs 2,279 on the NSE at 9:42 am on Monday. Zaynich is designed to treat complicated urinary tract infections (cUTI), including pyelonephritis, and targets infections caused by drug-resistant Gram-negative bacteria. The approval comes at a time when antimicrobial resistance is emerging as a growing global health challenge, limiting treatment options for physicians. For Wockhardt, the approval marks the culmination of years of investment in building a proprietary antibiotic research pipeline. With regulatory clearances now secured in both the US and India, the company has crossed a significant scientific hurdle that only a handful of Indian pharmaceutical firms have achieved. The focus now shifts to commercial execution. Having demonstrated its ability to discover and develop a globally relevant antibiotic, Wockhardt must prove that innovation can translate into sustainable revenue growth and profitability. "Here what you are seeing is our success in research, I want you to see success as a business," founder-chairman Dr Habil Khorakiwala had told Moneycontrol earlier this year, highlighting the company's ambition to convert scientific breakthroughs into commercial success. Wockhardt's antibiotic programme addresses a critical gap in the market left by large global pharmaceutical companies that have scaled back investments in antibiotic research. The company is focused on combating Gram-negative resistant infections, one of the most difficult and rapidly evolving threats in infectious diseases. According to company estimates, around two million patients globally suffer from Gram-negative resistant infections. Wockhardt pegs the total addressable market for Zaynich at nearly $9 billion across the US, Europe and India. In India alone, the company estimates that nearly 1.1 million resistant infection cases could be addressed by the drug, translating into a market opportunity of around Rs 17,000 crore. Across the US and Europe, Wockhardt estimates the addressable opportunity at roughly $7 billion.

**Companies:** Wockhardt
**Countries:** India, United States

[Read the full story on Moneycontrol](https://www.moneycontrol.com/news/business/markets/wockhardt-stock-soars-up-to-16-as-us-fda-clears-novel-antibiotic-zaynich-13937078.html)

---

Canonical: https://newsio.io/zh-TW/n/836ba6cd-ad36-43a7-986d-a9ad6af19454/wockhardt10fdazaynich
Summarized by Newsio from Moneycontrol. https://newsio.io/how-it-works